First-in-Class Antipsychotic Linked to Lower Cardiometabolic Risk First-in-Class Antipsychotic Linked to Lower Cardiometabolic Risk

A recently approved first-in-class antipsychotic appears to have fewer adverse cardiometabolic effects compared with placebo or standard care with risperidone, new research suggests.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Psychiatry News Source Type: news